Zinc supplementation improves glucose disposal in patients with cirrhosis

Metabolism: Clinical and Experimental

Volumn 47, Issue 7, 1998, Pages 792-798

  Marchesini, Giulio ^a   Bugianesi, Elisabetta ^b   Ronchi, Michela ^b   Flamia, Rita ^b   Thomaseth, Karl ^b   Pacini, Giovanni ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ZINC;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET SUPPLEMENTATION; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; LIVER CIRRHOSIS; MALE; NITROGEN METABOLISM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ZINC DEFICIENCY;

EID: 0031837619     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90114-7     Document Type: Article

References (53)

1. McClain CJ, Kasarskis EJ, Allen JJ: Functional consequences of zinc deficiency. Prog Food Nutr Sci 9:185-226, 1985
2. Riggio O, Merli M, Capocaccia L, et al: Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology 16:785-789, 1992
3. Marchesini G, Fabbri A, Bianchi GP, et al: Zinc supplementation and amino-acid nitrogen metabolism in patients with advanced cirrhosis. Hepatology 23:1084-1092, 1996
4. Scholmerich J, Lohla E, Gerok W: Zinc and vitamin A deficiency in liver cirrhosis. Hepatogastroenterol 30:119-125, 1983
5. Rabbani P, Prasad AS: Plasma ammonia and ornithine transcarbamylase activity in zinc-deficient rats. Am J Physiol 235:E203-E206, 1978
6. Reding G, Duchateau J, Bataille C: Oral zinc supplementation improves hepatic encephalopathy. Results of randomised controlled trial. Lancet 2:493-495, 1984
7. Riggio O, Ariosto F, Merli M, et al: Short-term oral zinc supplementation does not improve chronic hepatic encephalothy. Results of a double-blind crossover trial. Dig Dis Sci 36:1204-1208, 1991
8. Bresci G, Parisi G, Banti S: Management of hepatic encephalopathy with oral zinc supplementation. A long term treatment. Eur J Med 2:414-416, 1993
9. Conn HO, Schreiber W, Elkington SG: Cirrhosis and diabetes. II. Association of impaired glucose tolerance with porta-systemic shunting in Laennec's cirrhosis. Am J Dig Dis 16:227-239, 1971
10. Bianchi GP, Marchesini G, Zoli M, et al: Prognostic significance of diabetes in patients with liver cirrhosis. Hepatology 20:119-125, 1994
11. Iversen J, Vilstrup H, Tygstrup N: Kinetics of glucose metabolism in relation to insulin concentration in patients with alcoholic cirrhosis and in healthy persons. Gastroenterology 87:1138-1143, 1984
12. Marchesini G, Bianchi GP, Forlani G, et al: Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis. Dig Dis Sci 32:1118-1124, 1987
13. Marchesini G, Pacini G, Bianchi GP, et al: Glucose disposal, β-cell secretion, and hepatic insulin extraction in liver cirrhosis. A minimal model assessment. Gastroenterology 99:1715-1722, 1990
14. Kinlaw WB, Levine AS, Morley JE, et al: Abnormal zinc metabolism in type II diabetes mellitus. Am J Med 75:273-277, 1983
15. Levine AS, McClain CJ, Handwerger BS, et al: Tissue zinc status of genetically diabetic and streptozotocin-induced diabetic mice. Am J Clin Nutr 37:382-386, 1983
16. Quarterman J, Mills CF, Humphries WR: The reduced secretion of and sensitivity to insulin in zinc deficient rats. Biochem Biophys Res Commun 25:356-358, 1966
17. Brown ED, Penhos JC, Recant L, et al: Glucose tolerance, plasma and pancreatic insulin levels in zinc deficient rats. Proc Soc Exp Biol Med 150:557-560, 1975
18. Shisheva A, Shechter Y: Insulin-like effects of zinc ion in vitro and in vivo. Preferential effects on desensitized adipocytes and induction of normoglycemia in streptozotocin-induced rats. Diabetes 41:982-988, 1992
19. Brun JF, Guintrand-Hugret R, Fons C, et al: Effects of oral zinc gluconate on glucose effectiveness and insulin sensitivity in humans. Biol Trace Elem Res 47:385-391, 1995
20. Bergman RN: Toward physiological understanding of glucose tolerance minimal-model approach. Diabetes 38:1512-1527, 1989
21. Niewoehner CB, Allen JI, Boosalis M, et al: Role of zinc supplementation in type II diabetes mellitus. Am J Med 81:63-68, 1986
22. Cobelli C, Ruggeri A, DiStefano JJ, et al: Optimal design of multioutput sampling schedules. Software and applications to endocrine-metabolic and pharmacokinetic models. IEEE Trans Biomed Eng 32:249-256, 1985
23. Pacini G: Mathematical models of insulin secretion in physiological and clinical investigation. Comp Methods Programs Biomed 41:269-285, 1994
24. Kahn SE, Klaff LJ, Schwartz MW, et al: Treatment with a somatostatin analog decreases pancreatic β-cell and whole body sensitivity to glucose. J Clin Endocrinol Metab 71:994-1002, 1990
25. Cobelli C, Pacini G: Insulin secretion and hepatic extraction in humans by minimal modeling of C-peptide and insulin kinetics. Diabetes 37:223-232, 1988
26. Arquilla ER, Packer S, Tarmas W, et al: The effects of zinc on insulin metabolism. Endocrinology 103:1440-1449, 1987
27. Rossetti KL, Giaccari A, Klein-Robbenhaar E, et al: Insulinomimetic properties of trace elements and characterization of their in vivo mode of action. Diabetes 39:1243-1250, 1990
28. Vicario PP, Sperstein R, Bennun A: Role of divalent metals in the activation and regulation of insulin receptor tyrosine kinase. Biosystems 22:55-66, 1988
29. Faure P, Roussel AM, Martiniè M, et al: Insulin sensitivity in zinc-depleted rats: Assessment with the euglycaemic hyperinsulinic clamp technique. Diabete Metab 17:325-331, 1991
30. Heise CC, King JC, Costa FM, et al: Hyperzincuria in IDDM women: Relationship to measures of glycemic control, renal function, and tissue catabolism. Diabetes Care 11:780-786, 1988
31. Cunningham JJ, Fu A, Mearkle PL, et al: Hyperzincuria in individuals with insulin-dependent diabetes mellitus: Concurrent zinc status and the effects of high-dose zinc supplementation. Metabolism 43:1558-1562, 1994
32. Vallee BL, Wacker WEC, Bartholomay AF, et al: Zinc metabolism in hepatic dysfunction. I. Serum zinc concentrations in Laennec's cirrhosis and their validation by sequential analysis. N Engl J Med 255:403-408, 1956
33. Sullivan JF, Heaney RP: Zinc metabolism in alcoholic cirrhosis. Am J Clin Nutr 23:170-177, 1970
34. Petrides AS, Schulze-Berge D, Vogt C, et al: Glucose resistance contributes to diabetes mellitus in cirrhosis. Hepatology 18:284-291, 1993
35. Kruszynska JT, Harry DS, Bergman RN, et al: Insulin sensitivity, insulin secretion, and glucose effectiveness in diabetic and non-diabetic cirrhotic patients. Diabetologia 36:121-128, 1993
36. Best JD, Kahn SE, Ader M, et al: Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 19:1018-1030, 1996
37. Shmueli E, Walker M, Alberti KGMM, et al: Normal splanchnic but impaired peripheral insulin-stimulated glucose uptake in cirrhosis. Hepatology 188:86-95, 1993
38. Nygren A, Adner N, Sundblad L, et al: Insulin uptake by the human alcoholic cirrhotic liver. Metabolism 34:48-52, 1985
39. Ader M, Pacini G, Yang YJ, et al: Importance of glucose per se to intravenous glucose tolerance. Diabetes 34:1092-1103, 1985
40. Bergman RN, Hope ID, Yang JY, et al: Assessment of insulin sensitivity in vivo: A critical review. Diabetes Metab Rev 5:411-429, 1989
41. Cobelli C, Ruggeri A, Toffolo G, et al: Is the "pool fraction" paradigm a valid model for the assessment of in vivo turnover in non-steady state? Am J Physiol 245:R624-R632, 1983
42. McCullough AJ, Mullen KD, Kahlan SC: Measurements of total body water and extracellular water in cirrhotic patients with and without ascites. Hepatology 14:1102-1111, 1991
43. 2+) stimulate glucose transport activity by post-insulin receptor kinase mechanism in rat adipocytes. J Biol Chem 264:16118-16122, 1989
44. Carruthers A: Facilitated diffusion of glucose. Physiol Rev 70:1135-1176, 1990
45. 2+-dependent mechanism. Diabetes 44:1345-1348, 1995
46. Prasad AS: Zinc deficiency in women, infants and children. J Am Coll Nutr 15:113-120, 1996
47. Nishi Y: Zinc and growth. J Am Coll Nutr 15:340-344, 1996
48. Di Cola G, Cool MH, Accili D: Hypoglycemic effect of insulin-like growth factor-I in mice lacking insulin receptors. J Clin Invest 99:2538-2544, 1997
49. Kolaczynski JW, Caro JF: Insulin-like growth factor-I therapy in diabetes: Physiologic basis, clinical benefits and risks. Ann Intern Med 120:47-55, 1994
50. Shmueli E, Miell JP, Stewart M, et al: High insulin-like growth factor binding protein 1 levels in cirrhosis: Link with insulin resistance. Hepatology 24:127-133, 1996
51. Finegood DT: Application of the minimal model of glucose kinetics, in Bergman RN, Lovejoy JC (eds): The Minimal Model Approach and Determinants of Glucose Tolerance. Baton Rouge, LA, Louisiana State University, 1997, pp 51-122
52. Avogaro A, Vicini P, Valerio A, et al: The hot but not the cold minimal model allows precise assessment of insulin sensitivity in NIDDM subjects. Am J Physiol 270:E532-E540, 1996
53. Heise CC, King JC, Costa FM, et al: Hyperzincuria in IDDM women. Relationship to measures of glycemic control, renal function, and tissue catabolism. Diabetes Care 11:780-786, 1988